

**GOVERNMENT OF INDIA  
MINISTRY OF HEALTH AND FAMILY WELFARE  
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA  
UNSTARRED QUESTION NO.96  
TO BE ANSWERED ON 2<sup>ND</sup> FEBRUARY, 2021**

**PRICING AND SUPPLY AGREEMENT WITH SII**

**96 SHRI DEREK O' BRIEN:**

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether Government has finalized a pricing and supply agreement with Serum Institute of India (SII) Limited for COVID-19 vaccines
- (b) if so, the time when the pricing and supply agreement for the vaccine was finalized, if not, the reasons therefor
- (c) when was the approval granted to Oxford/AstraZeneca COVID-19 vaccine in India and
- (d) whether it is a fact that multiple doses of the vaccine produced for India could not be rolled out despite approval due to the lack of a formal agreement for supply, if so, the details thereof, if not, the reasons therefor?

**ANSWER  
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND  
FAMILY WELFARE  
(SHRI ASHWINI KUMAR CHOUBEY)**

- (a) & (b): Yes, for procurement of COVID-19 vaccines, the Supply Order dated 11<sup>th</sup> January 2021 was placed with Serum Institute of India (SII) Limited.
- (c): The vaccine (Covishield) of M/s Serum Institute of India, Pune, with technology transfer from AstraZeneca/Oxford University, was approved for restricted use in emergency situation by the Central Drugs Standard Control Organization (CDSCO).
- (d): No. As per protocol, the Supply Order for COVID-19 vaccines, specifying the number of vaccine doses, was placed with the manufacturer and vaccines were delivered within 3 days to the States/UTs and other consignee points.